/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

KALA BIO Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.13 -0.1591(-15.91%) KALA at 04 Dec 2025 04:36 PM Biotechnology
Lowest Today 0.9082
Highest Today 1.1
Today’s Open 1.03
Prev. Close 1.1
52 Week High 20.60
52 Week Low 0.61
Day’s Range: Low 0.9082 High 1.1
52-Week Range: Low 0.61 High 20.60
1 day return -
1 Week return +0.39
1 month return +26.27
3 month return -93.39
6 month return -75.5
1 year return -84.87
3 year return -80.69
5 year return -99.74
10 year return -

Institutional Holdings

Baker Bros Advisors LP 17.12

Cormorant Asset Management, LLC 8.59

SR ONE CAPITAL MANAGEMENT, LP 8.53

Woodline Partners LP 4.28

AIGH Capital Management, LLC 4.27

Vanguard Group Inc 2.43

ADAR1 Capital Management LLC 2.13

UBS O'Connor LLC 1.97

Vanguard Total Stock Mkt Idx Inv 1.61

Geode Capital Management, LLC 0.80

Perceptive Advisors LLC 0.79

Vanguard Institutional Extnd Mkt Idx Tr 0.76

Fidelity Extended Market Index 0.40

BlackRock Inc 0.30

Renaissance Technologies Corp 0.25

XTX Topco Ltd 0.19

Fidelity Total Market Index 0.17

Northern Trust Corp 0.15

Extended Equity Market Fund K 0.13

Fidelity Series Total Market Index 0.10

Spartan Extended Market Index Pool F 0.09

Northern Trust Extended Eq Market Idx 0.08

NT Ext Equity Mkt Idx Fd - L 0.08

NT Ext Equity Mkt Idx Fd - NL 0.07

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.05

Spartan Total Market Index Pool G 0.05

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

Tower Research Capital LLC 0.02

Covestor Ltd 0.02

Extended Equity Market Fund M 0.02

Morgan Stanley - Brokerage Accounts 0.01

Vanguard U.S. Eq Idx £ Acc 0.01

Fidelity Nasdaq Composite Index 0.01

Blackrock US Eq Mkt Fund CF 0.01

NT Ext Eq Mkt Indx Fd DC Lend T3 0.01

U.S. Equity Market Fund F 0.01

State St US Extended Mkt Indx NL Cl C 0.01

Mccormack Advisors International 0.00

JPMorgan Chase & Co 0.00

Steward Partners Investment Advisory, LLC 0.00

Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 9.03 M

PB Ratio 8.3424

PE Ratio 0.0

Enterprise Value 16.78 M

Total Assets 55.48 M

Volume 7451465

Company Financials

Annual Revenue FY23:0 0.0M, FY22:3892000 3.9M, FY21:11240000 11.2M, FY20:6362000 6.4M, FY19:6074000 6.1M

Annual Profit FY23:0 0.0M, FY22:1332000 1.3M, FY21:7143000 7.1M, FY20:3189000 3.2M, FY19:4066000 4.1M

Annual Net worth FY23:-46415000 -46.4M, FY22:-223000 -0.2M, FY21:-152296000 -152.3M, FY20:-112004000 -112.0M, FY19:-101984000 -102.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-67000 -0.1M, Q1/2025:-68000 -0.1M, Q3/2024:null 0.0M, Q2/2024:-61000 -0.1M

Quarterly Net worth Q3/2025:-7564000 -7.6M, Q2/2025:-11155000 -11.2M, Q1/2025:-8947000 -8.9M, Q3/2024:-8950000 -9.0M, Q2/2024:-9579000 -9.6M

Fund house & investment objective

Company Information KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Organisation Biotechnology

Employees 38

Industry Biotechnology

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow